HOMEPRODUCTSSERVICESCOMPANYCONTACTFAQResearchDictionaryPharmaMobileSign Up FREE or Login

AG 014699

Also Known As:
AG-014699; AG014699
Networked: 13 relevant articles (3 outcomes, 3 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Experts

1. Thomas, Huw D: 4 articles (12/2011 - 02/2009)
2. Curtin, Nicola J: 4 articles (12/2011 - 02/2009)
3. Kyle, Suzanne: 3 articles (12/2011 - 10/2009)
4. Sun, Ying: 2 articles (05/2014 - 04/2014)
5. Li, Li: 2 articles (05/2014 - 04/2014)
6. Ding, Huan: 2 articles (05/2014 - 04/2014)
7. Los, Gerrit: 2 articles (06/2013 - 02/2011)
8. Ali, Majid: 2 articles (12/2011 - 10/2009)
9. Telfer, Brian A: 2 articles (12/2011 - 10/2009)
10. Williams, Kaye J: 2 articles (12/2011 - 10/2009)

Related Diseases

1. Neoplasms (Cancer)
2. Breast Neoplasms (Breast Cancer)
05/01/2014 - "INPP4B overexpression enhances the antitumor efficacy of PARP inhibitor AG014699 in MDA-MB-231 triple-negative breast cancer cells."
02/16/2011 - "We undertook, to our knowledge, the first comprehensive in vitro and in vivo investigations of the antitumor activity of the PARP inhibitor AG014699 in human cancer cells carrying mutated or epigenetically silenced BRCA1/2. We used nine human cell lines, four with nonmutated BRCA1/2 (MCF7, MDA-MB-231, and HCC1937-BRCA1 [breast cancer] and OSEC-2 [ovarian surface epithelial]), two with mutated BRCA1 (MDA-MB-436 and HCC1937 [breast cancer]), one with mutated BRCA2 (CAPAN-1 [pancreatic cancer]), one that was heterozygous for BRCA2 (OSEC-1 [ovarian surface epithelial]), and one with epigenetically silenced BRCA1 (UACC3199 [breast cancer]), and two Chinese hamster ovary cell lines, parental AA8 and XRCC3 mutated IRS 1SF. "
04/01/2014 - "[Effects of poly(ADP-ribose)polymerase inhibitor AG014699 combined with chemotherapy on the proliferation of triple-negative breast cancer cell line MDA-MB-231]."
05/01/2014 - "The main aim of this study was to evaluate whether overexpressing inositol polyphosphate 4-phosphatase type II (INPP4B) gene, a novel tumor suppressor gene negatively regulating the phosphatidylinositol 3-kinase (PI3K)/AKT signaling pathway, could enhance the antitumor efficacy of PARP inhibitor AG014699 used in the treatment of triple-negative breast cancer (TNBC). "
04/01/2014 - "To observe the effects of poly(ADP-ribose)polymerase (PARP) inhibitor AG014699 alone and combined with docetaxel (DTX) or carboplatin (CBP) on the proliferation of triple-negative breast cancer cell line MDA-MB-231 and to investigate whether PARP inhibitor AG014699 combined with chemotherapy could play a synergistic antitumor effect. "
3. Pancreatic Neoplasms (Pancreatic Cancer)
4. Ovarian Neoplasms (Ovarian Cancer)
5. Neuroblastoma

Related Drugs and Biologics

1. glucuronyl glucosamine glycan sulfate (Vessel)
2. Phosphatidylinositol 3-Kinase (1 Phosphatidylinositol 3 Kinase)
3. Doxorubicin (Adriamycin)
4. phosphatidylinositol-3,4-bisphosphate 4-phosphatase
5. Niacinamide (Nicotinamide)
6. 1- (4- dimethylaminomethylphenyl)- 8,9- dihydro- 7H- 2,7,9a- benzo(cd)azulen- 6- one
7. Poly(ADP-ribose) Polymerases (Poly ADP Ribose Polymerase)
8. temozolomide (Temodar)
9. Carboplatin (JM8)
10. Carbon Monoxide

Related Therapies and Procedures

1. Heterologous Transplantation (Xenotransplantation)
2. Drug Therapy (Chemotherapy)